Global Pompe Diseases Market Size study, by Route of Administration (Oral, Parenteral), By Treatment Type (Substrate Reduction Therapy (SRT), Enzyme Replacement Therapy (ERT), Chaperone-Advanced Replacement Therapy (CART), Supportive Care), By End User (H

Global Pompe Diseases Market Size study, by Route of Administration (Oral, Parenteral), By Treatment Type (Substrate Reduction Therapy (SRT), Enzyme Replacement Therapy (ERT), Chaperone-Advanced Replacement Therapy (CART), Supportive Care), By End User (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, Others) and Regional Forecasts 2022-2028

Global Pompe Diseases Market is valued at approximately USD XXX million in 2021 and is anticipated to grow with a healthy growth rate of more than 4.5% over the forecast period 2022-2028. Pompe disease is a disorder affected by the buildup of a complex sugar called glycogen in the body's cells. It is inherited genetically, and the buildup of glycogen in some tissues and organs, especially muscles, makes them less able to operate normally. In the United States, one in 40,000 people have Pompe disease. The market growth is driven by key factors such as launch of novel drugs and the continued uptake of long-term therapies and increasing development in the field of enzyme replacement therapies. For instance, Enzyme replacement therapy (ERT), which involves giving rhGAA intravenously, is the only treatment for Pompe illness that has been approved, according to a paper titled ""Pharmacological Chaperone Therapy for Pompe Disease"" that was published in the Journal of Molecules in November 2021. Researchers are looking for novel treatments because of the shortcomings of ERT. which is the sole medication acknowledged by the US Food and Drug Administration. Furthermore, in August 2021, Enzyme Replacement therapy “Aval glucosidase Alfa” has been approved by United State of Food and Drug Administration, for the patient aged 1 year and older with late onset pompe disease. Moreover, emerging immunotherapeutic approaches for Pompe disease create lucrative opportunity for the market in upcoming years. However, high Treatment Cost impedes the growth of the market over the forecast period of 2022-2028

The key regions considered for the global Pompe Diseases Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is leading the overall market share owing to rising launches of novel drugs and growing research and development expenditure. However, Asia Pacific is expected to be the fastest growing region due to growing awareness among patients regarding rare disorders and increase in the prevalence of pompe disease in the region.

Major market players included in this report are:
Amicus Therapeutics
CENTOGENE AG
Valerion Therapeutics
Astellas Pharma
EpiVax, Inc
Oxyrane
Sanofi
AVROBIO, Inc.
Genethon
Sangamo Therapeutics

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Application offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Route of Administration:
Oral
Parenteral
By Treatment Type:
Substrate Reduction Therapy (SRT)
Enzyme Replacement Therapy (ERT)
Chaperone-Advanced Replacement Therapy (CART)
Supportive Care
By End User:
Hospitals
Diagnostic Centers
Ambulatory Surgical Centers
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Pompe Diseases Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Amicus Therapeutics
CENTOGENE AG
Valerion Therapeutics
Astellas Pharma
EpiVax, Inc
Oxyrane
Sanofi
AVROBIO, Inc.
Genethon
Sangamo Therapeutics

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.